Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’
Eli Lilly has released initial clinical data for its AJX-101 drug, acquired through the $2.3 billion purchase of Ajax Therapeutics. The study shows the type II JAK2 inhibitor is effective in treating myelofibrosis patients who failed previous therapies.
Why it matters
This data validates a high-value acquisition and offers a potential new treatment pathway for patients with limited options for myeloproliferative neoplasms.
Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’ By Angus Liu Jun 13, 2026 11:15am Eli Lilly M&A myelofibrosis Incyte --> Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.
The article focuses on industry news and clinical trial results without editorializing the financial or medical outcomes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in